The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Cancer Biologics Market Research Report 2024

Global Cancer Biologics Market Research Report 2024

Publishing Date : May, 2024

License Type :
 

Report Code : 1719285

No of Pages : 107

Ask Your Query

Synopsis

Cancer Biologic is a medicinal preparation created by a biological process, it is used to treatment and remission cancer symptoms.

The global Cancer Biologics market was valued at US$ 161690 million in 2023 and is anticipated to reach US$ 352340 million by 2030, witnessing a CAGR of 12.5% during the forecast period 2024-2030.

North American market for Cancer Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Cancer Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Cancer Biologics in Lung Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Cancer Biologics include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca and Merck & Co, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Cancer Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Biologics.

Report Scope

The Cancer Biologics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cancer Biologics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • AbbVie
  • Johnson & Johnson
  • Novartis
  • Gilead Sciences
  • Roche
  • Bristol-Myers Squibb
  • Amgen
  • AstraZeneca
  • Merck & Co
  • Takeda
  • Merck KGaA
  • Seagen
  • Eli Lilly
  • Ono Pharmaceutical
  • Pfizer
  • GSK
  • Exelixis
  • Regeneron
  • Innovent
  • Hengrui Medicine

Segment by Type

  • Monoclonal Antibodies
  • Vaccines
  • Cell and Gene Therapy
  • Others

Segment by Application

  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood-related Cancer
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Netherlands)
  • Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
  • Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Biologics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Biologics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Vaccines
1.2.4 Cell and Gene Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Cancer Biologics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Prostate Cancer
1.3.5 Blood-related Cancer
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Biologics Market Perspective (2019-2030)
2.2 Cancer Biologics Growth Trends by Region
2.2.1 Global Cancer Biologics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cancer Biologics Historic Market Size by Region (2019-2024)
2.2.3 Cancer Biologics Forecasted Market Size by Region (2025-2030)
2.3 Cancer Biologics Market Dynamics
2.3.1 Cancer Biologics Industry Trends
2.3.2 Cancer Biologics Market Drivers
2.3.3 Cancer Biologics Market Challenges
2.3.4 Cancer Biologics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Biologics Players by Revenue
3.1.1 Global Top Cancer Biologics Players by Revenue (2019-2024)
3.1.2 Global Cancer Biologics Revenue Market Share by Players (2019-2024)
3.2 Global Cancer Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Biologics Revenue
3.4 Global Cancer Biologics Market Concentration Ratio
3.4.1 Global Cancer Biologics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Biologics Revenue in 2023
3.5 Cancer Biologics Key Players Head office and Area Served
3.6 Key Players Cancer Biologics Product Solution and Service
3.7 Date of Enter into Cancer Biologics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Biologics Breakdown Data by Type
4.1 Global Cancer Biologics Historic Market Size by Type (2019-2024)
4.2 Global Cancer Biologics Forecasted Market Size by Type (2025-2030)
5 Cancer Biologics Breakdown Data by Application
5.1 Global Cancer Biologics Historic Market Size by Application (2019-2024)
5.2 Global Cancer Biologics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cancer Biologics Market Size (2019-2030)
6.2 North America Cancer Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cancer Biologics Market Size by Country (2019-2024)
6.4 North America Cancer Biologics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Biologics Market Size (2019-2030)
7.2 Europe Cancer Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cancer Biologics Market Size by Country (2019-2024)
7.4 Europe Cancer Biologics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Biologics Market Size (2019-2030)
8.2 Asia-Pacific Cancer Biologics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cancer Biologics Market Size by Region (2019-2024)
8.4 Asia-Pacific Cancer Biologics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Biologics Market Size (2019-2030)
9.2 Latin America Cancer Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cancer Biologics Market Size by Country (2019-2024)
9.4 Latin America Cancer Biologics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Biologics Market Size (2019-2030)
10.2 Middle East & Africa Cancer Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cancer Biologics Market Size by Country (2019-2024)
10.4 Middle East & Africa Cancer Biologics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Cancer Biologics Introduction
11.1.4 AbbVie Revenue in Cancer Biologics Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Cancer Biologics Introduction
11.2.4 Johnson & Johnson Revenue in Cancer Biologics Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Cancer Biologics Introduction
11.3.4 Novartis Revenue in Cancer Biologics Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Detail
11.4.2 Gilead Sciences Business Overview
11.4.3 Gilead Sciences Cancer Biologics Introduction
11.4.4 Gilead Sciences Revenue in Cancer Biologics Business (2019-2024)
11.4.5 Gilead Sciences Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Cancer Biologics Introduction
11.5.4 Roche Revenue in Cancer Biologics Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Cancer Biologics Introduction
11.6.4 Bristol-Myers Squibb Revenue in Cancer Biologics Business (2019-2024)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Amgen
11.7.1 Amgen Company Detail
11.7.2 Amgen Business Overview
11.7.3 Amgen Cancer Biologics Introduction
11.7.4 Amgen Revenue in Cancer Biologics Business (2019-2024)
11.7.5 Amgen Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Cancer Biologics Introduction
11.8.4 AstraZeneca Revenue in Cancer Biologics Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 Merck & Co
11.9.1 Merck & Co Company Detail
11.9.2 Merck & Co Business Overview
11.9.3 Merck & Co Cancer Biologics Introduction
11.9.4 Merck & Co Revenue in Cancer Biologics Business (2019-2024)
11.9.5 Merck & Co Recent Development
11.10 Takeda
11.10.1 Takeda Company Detail
11.10.2 Takeda Business Overview
11.10.3 Takeda Cancer Biologics Introduction
11.10.4 Takeda Revenue in Cancer Biologics Business (2019-2024)
11.10.5 Takeda Recent Development
11.11 Merck KGaA
11.11.1 Merck KGaA Company Detail
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Cancer Biologics Introduction
11.11.4 Merck KGaA Revenue in Cancer Biologics Business (2019-2024)
11.11.5 Merck KGaA Recent Development
11.12 Seagen
11.12.1 Seagen Company Detail
11.12.2 Seagen Business Overview
11.12.3 Seagen Cancer Biologics Introduction
11.12.4 Seagen Revenue in Cancer Biologics Business (2019-2024)
11.12.5 Seagen Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Detail
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Cancer Biologics Introduction
11.13.4 Eli Lilly Revenue in Cancer Biologics Business (2019-2024)
11.13.5 Eli Lilly Recent Development
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Detail
11.14.2 Ono Pharmaceutical Business Overview
11.14.3 Ono Pharmaceutical Cancer Biologics Introduction
11.14.4 Ono Pharmaceutical Revenue in Cancer Biologics Business (2019-2024)
11.14.5 Ono Pharmaceutical Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Detail
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Cancer Biologics Introduction
11.15.4 Pfizer Revenue in Cancer Biologics Business (2019-2024)
11.15.5 Pfizer Recent Development
11.16 GSK
11.16.1 GSK Company Detail
11.16.2 GSK Business Overview
11.16.3 GSK Cancer Biologics Introduction
11.16.4 GSK Revenue in Cancer Biologics Business (2019-2024)
11.16.5 GSK Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Detail
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Cancer Biologics Introduction
11.17.4 Exelixis Revenue in Cancer Biologics Business (2019-2024)
11.17.5 Exelixis Recent Development
11.18 Regeneron
11.18.1 Regeneron Company Detail
11.18.2 Regeneron Business Overview
11.18.3 Regeneron Cancer Biologics Introduction
11.18.4 Regeneron Revenue in Cancer Biologics Business (2019-2024)
11.18.5 Regeneron Recent Development
11.19 Innovent
11.19.1 Innovent Company Detail
11.19.2 Innovent Business Overview
11.19.3 Innovent Cancer Biologics Introduction
11.19.4 Innovent Revenue in Cancer Biologics Business (2019-2024)
11.19.5 Innovent Recent Development
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Detail
11.20.2 Hengrui Medicine Business Overview
11.20.3 Hengrui Medicine Cancer Biologics Introduction
11.20.4 Hengrui Medicine Revenue in Cancer Biologics Business (2019-2024)
11.20.5 Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Cancer Biologics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Vaccines
Table 4. Key Players of Cell and Gene Therapy
Table 5. Key Players of Others
Table 6. Global Cancer Biologics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Cancer Biologics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Cancer Biologics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Cancer Biologics Market Share by Region (2019-2024)
Table 10. Global Cancer Biologics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Cancer Biologics Market Share by Region (2025-2030)
Table 12. Cancer Biologics Market Trends
Table 13. Cancer Biologics Market Drivers
Table 14. Cancer Biologics Market Challenges
Table 15. Cancer Biologics Market Restraints
Table 16. Global Cancer Biologics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Cancer Biologics Market Share by Players (2019-2024)
Table 18. Global Top Cancer Biologics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biologics as of 2023)
Table 19. Ranking of Global Top Cancer Biologics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Cancer Biologics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Cancer Biologics Product Solution and Service
Table 23. Date of Enter into Cancer Biologics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Cancer Biologics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Cancer Biologics Revenue Market Share by Type (2019-2024)
Table 27. Global Cancer Biologics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Cancer Biologics Revenue Market Share by Type (2025-2030)
Table 29. Global Cancer Biologics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Cancer Biologics Revenue Market Share by Application (2019-2024)
Table 31. Global Cancer Biologics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Cancer Biologics Revenue Market Share by Application (2025-2030)
Table 33. North America Cancer Biologics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Cancer Biologics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Cancer Biologics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Cancer Biologics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Cancer Biologics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Cancer Biologics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Cancer Biologics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Cancer Biologics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Cancer Biologics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Cancer Biologics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Cancer Biologics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Cancer Biologics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Cancer Biologics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Cancer Biologics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Cancer Biologics Market Size by Country (2025-2030) & (US$ Million)
Table 48. AbbVie Company Detail
Table 49. AbbVie Business Overview
Table 50. AbbVie Cancer Biologics Product
Table 51. AbbVie Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 52. AbbVie Recent Development
Table 53. Johnson & Johnson Company Detail
Table 54. Johnson & Johnson Business Overview
Table 55. Johnson & Johnson Cancer Biologics Product
Table 56. Johnson & Johnson Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 57. Johnson & Johnson Recent Development
Table 58. Novartis Company Detail
Table 59. Novartis Business Overview
Table 60. Novartis Cancer Biologics Product
Table 61. Novartis Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 62. Novartis Recent Development
Table 63. Gilead Sciences Company Detail
Table 64. Gilead Sciences Business Overview
Table 65. Gilead Sciences Cancer Biologics Product
Table 66. Gilead Sciences Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 67. Gilead Sciences Recent Development
Table 68. Roche Company Detail
Table 69. Roche Business Overview
Table 70. Roche Cancer Biologics Product
Table 71. Roche Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 72. Roche Recent Development
Table 73. Bristol-Myers Squibb Company Detail
Table 74. Bristol-Myers Squibb Business Overview
Table 75. Bristol-Myers Squibb Cancer Biologics Product
Table 76. Bristol-Myers Squibb Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 77. Bristol-Myers Squibb Recent Development
Table 78. Amgen Company Detail
Table 79. Amgen Business Overview
Table 80. Amgen Cancer Biologics Product
Table 81. Amgen Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 82. Amgen Recent Development
Table 83. AstraZeneca Company Detail
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Cancer Biologics Product
Table 86. AstraZeneca Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 87. AstraZeneca Recent Development
Table 88. Merck & Co Company Detail
Table 89. Merck & Co Business Overview
Table 90. Merck & Co Cancer Biologics Product
Table 91. Merck & Co Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 92. Merck & Co Recent Development
Table 93. Takeda Company Detail
Table 94. Takeda Business Overview
Table 95. Takeda Cancer Biologics Product
Table 96. Takeda Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 97. Takeda Recent Development
Table 98. Merck KGaA Company Detail
Table 99. Merck KGaA Business Overview
Table 100. Merck KGaA Cancer Biologics Product
Table 101. Merck KGaA Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 102. Merck KGaA Recent Development
Table 103. Seagen Company Detail
Table 104. Seagen Business Overview
Table 105. Seagen Cancer Biologics Product
Table 106. Seagen Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 107. Seagen Recent Development
Table 108. Eli Lilly Company Detail
Table 109. Eli Lilly Business Overview
Table 110. Eli Lilly Cancer Biologics Product
Table 111. Eli Lilly Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 112. Eli Lilly Recent Development
Table 113. Ono Pharmaceutical Company Detail
Table 114. Ono Pharmaceutical Business Overview
Table 115. Ono Pharmaceutical Cancer Biologics Product
Table 116. Ono Pharmaceutical Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 117. Ono Pharmaceutical Recent Development
Table 118. Pfizer Company Detail
Table 119. Pfizer Business Overview
Table 120. Pfizer Cancer Biologics Product
Table 121. Pfizer Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 122. Pfizer Recent Development
Table 123. GSK Company Detail
Table 124. GSK Business Overview
Table 125. GSK Cancer Biologics Product
Table 126. GSK Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 127. GSK Recent Development
Table 128. Exelixis Company Detail
Table 129. Exelixis Business Overview
Table 130. Exelixis Cancer Biologics Product
Table 131. Exelixis Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 132. Exelixis Recent Development
Table 133. Regeneron Company Detail
Table 134. Regeneron Business Overview
Table 135. Regeneron Cancer Biologics Product
Table 136. Regeneron Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 137. Regeneron Recent Development
Table 138. Innovent Company Detail
Table 139. Innovent Business Overview
Table 140. Innovent Cancer Biologics Product
Table 141. Innovent Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 142. Innovent Recent Development
Table 143. Hengrui Medicine Company Detail
Table 144. Hengrui Medicine Business Overview
Table 145. Hengrui Medicine Cancer Biologics Product
Table 146. Hengrui Medicine Revenue in Cancer Biologics Business (2019-2024) & (US$ Million)
Table 147. Hengrui Medicine Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Biologics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Cancer Biologics Market Share by Type: 2023 VS 2030
Figure 3. Monoclonal Antibodies Features
Figure 4. Vaccines Features
Figure 5. Cell and Gene Therapy Features
Figure 6. Others Features
Figure 7. Global Cancer Biologics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Cancer Biologics Market Share by Application: 2023 VS 2030
Figure 9. Lung Cancer Case Studies
Figure 10. Breast Cancer Case Studies
Figure 11. Prostate Cancer Case Studies
Figure 12. Blood-related Cancer Case Studies
Figure 13. Other Case Studies
Figure 14. Cancer Biologics Report Years Considered
Figure 15. Global Cancer Biologics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Cancer Biologics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Cancer Biologics Market Share by Region: 2023 VS 2030
Figure 18. Global Cancer Biologics Market Share by Players in 2023
Figure 19. Global Top Cancer Biologics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biologics as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Cancer Biologics Revenue in 2023
Figure 21. North America Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Cancer Biologics Market Share by Country (2019-2030)
Figure 23. United States Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Cancer Biologics Market Share by Country (2019-2030)
Figure 27. Germany Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Cancer Biologics Market Share by Region (2019-2030)
Figure 35. China Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Cancer Biologics Market Share by Country (2019-2030)
Figure 43. Mexico Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Cancer Biologics Market Share by Country (2019-2030)
Figure 47. Turkey Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Cancer Biologics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. AbbVie Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 50. Johnson & Johnson Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 51. Novartis Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 52. Gilead Sciences Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 53. Roche Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 55. Amgen Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 56. AstraZeneca Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 57. Merck & Co Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 58. Takeda Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 59. Merck KGaA Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 60. Seagen Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 61. Eli Lilly Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 62. Ono Pharmaceutical Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 63. Pfizer Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 64. GSK Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 65. Exelixis Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 66. Regeneron Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 67. Innovent Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 68. Hengrui Medicine Revenue Growth Rate in Cancer Biologics Business (2019-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock